Age (years)b | 24.1±7.9 | 23.2±8.2 | 23.3±8.1 | 0.844 |
Gender, male: femalea | 2:5 | 17:15 | 19:20 | 0.407 |
Hospitalization period (days)b | 14.1±3.2 | 14.0±4.6 | 14.0±4.4 | 0.507 |
Severity | | | | |
Objective SCORAD indexb | 67.4±13.0 | 64.8±14.0 | 65.3±13.8 | 0.578 |
Erythemab | 2.4±0.7 | 2.4±0.5 | 2.4±0.5 | 0.761 |
Papule/edemab | 1.0±0.9 | 1.6±0.8 | 1.5±0.8 | 0.097 |
Oozing/crustb | 2.1±0.6 | 1.8±0.9 | 1.9±0.9 | 0.419 |
Excoriationb | 1.9±0.4 | 2.1±0.9 | 2.0±0.8 | 0.419 |
Lichenificationb | 2.4±0.7 | 2.0±1.1 | 2.1±1.0 | 0.484 |
Drynessb | 2.7±0.7 | 2.3±1.1 | 2.4±1.0 | 0.113 |
Area of skin lesions (%)b | 54.1±27.3 | 49.0±23.8 | 49.9±24.6 | 0.654 |
Infectious complicationsa | 2 (28.6%) | 5 (15.6%) | 7 (18.0%) | 0.603 |
Laboratory findings | | | | |
Serum total IgE (IU/㎖)b | 6287.5±5929.0 | 3541.5±5747.7 (n=30) | 4061.0±5881.6 (n=37) | 0.092 |
Eosinophil count (/㎕)b | 1089.0±620.8 | 1037.0±671.4 | 1046.3±662.9 | 0.929 |
Adherence to treatmenta | 2 (28.6%) | 25 (78.1%) | 27 (84.4%) | 0.020* |
Concomitant medications | | | | |
Antihistaminesa | 5 (71.4%) | 25 (78.1%) | 30 (76.9%) | 0.653 |
Topical corticosteroidsa | 0 (0%) | 3 (9.4%) | 3 (7.7%) | 1.000 |